atracurium besylate

Modify Date: 2024-01-02 14:08:48

atracurium besylate structure	Common Name	atracurium besylate
	CAS Number	64228-81-5	Molecular Weight	1243.479
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₆₅H₈₂N₂O₁₈S₂	Melting Point	85-90ºC
	MSDS	N/A	Flash Point	N/A

Use of atracurium besylate

Atracurium Besylate is a neuromuscular blocking agent with ED95 of 0.2 mg/kg. Target: nAChRAtracurium besylate is a neuromuscular-blocking drug or skeletal muscle relaxant in the category of non-depolarizing neuromuscular-blocking drugs, used adjunctively in anesthesia to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Atracurium is classified as an intermediate-duration non-depolarizing neuromuscular-blocking agent [1]. A 14C radiolabeled metabolism study in cats confirmed the lack of hepatic or renal involvement in the metabolism of atracurium: radioactivity eliminated in bile and urine was predominantly from metabolites rather than the unchanged parent drug [2].

Name	atracurium besylate
Synonym	More Synonyms

Description	Atracurium Besylate is a neuromuscular blocking agent with ED95 of 0.2 mg/kg. Target: nAChRAtracurium besylate is a neuromuscular-blocking drug or skeletal muscle relaxant in the category of non-depolarizing neuromuscular-blocking drugs, used adjunctively in anesthesia to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Atracurium is classified as an intermediate-duration non-depolarizing neuromuscular-blocking agent [1]. A 14C radiolabeled metabolism study in cats confirmed the lack of hepatic or renal involvement in the metabolism of atracurium: radioactivity eliminated in bile and urine was predominantly from metabolites rather than the unchanged parent drug [2].
Related Catalog	Signaling Pathways >> Membrane Transporter/Ion Channel >> nAChR Signaling Pathways >> Neuronal Signaling >> nAChR Research Areas >> Neurological Disease
References	[1]. Fagerlund, M.J., M. Dabrowski, and L.I. Eriksson, Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology, 2009. 110(6): p. 1244-1252. [2]. Neill, E. and D. Chapple, Metabolic studies in the cat with atracurium: a neuromuscular blocking agent designed for non-enzymic inactivation at physiological pH. Xenobiotica, 1982. 12(3): p. 203-210.

Description

Related Catalog

Signaling Pathways >> Membrane Transporter/Ion Channel >> nAChR

Signaling Pathways >> Neuronal Signaling >> nAChR

Research Areas >> Neurological Disease

References

[1]. Fagerlund, M.J., M. Dabrowski, and L.I. Eriksson, Pharmacological characteristics of the inhibition of nondepolarizing neuromuscular blocking agents at human adult muscle nicotinic acetylcholine receptor. Anesthesiology, 2009. 110(6): p. 1244-1252.

[2]. Neill, E. and D. Chapple, Metabolic studies in the cat with atracurium: a neuromuscular blocking agent designed for non-enzymic inactivation at physiological pH. Xenobiotica, 1982. 12(3): p. 203-210.

Melting Point	85-90ºC
Molecular Formula	C₆₅H₈₂N₂O₁₈S₂
Molecular Weight	1243.479
Exact Mass	1242.500366
PSA	257.60000
LogP	11.32610
Storage condition	2-8°C
Water Solubility	H2O: ~27 mg/mL

atracurium besylate MSDS(Chinese)

RIDADR	NONH for all modes of transport
WGK Germany	3

Atracurium oxalate

CAS#:64228-78-0

Methyl benzenes...

CAS#:80-18-2

~86%

atracurium besylate

CAS#:64228-81-5

Literature: Stenlake; Waigh; Dewar; et al. European Journal of Medicinal Chemistry, 1981 , vol. 16, # 6 p. 515 - 524

3,4-Dimethoxyph...

CAS#:93-40-3

atracurium besylate

CAS#:64228-81-5